Fig. 1From: Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patientsFlowchart showing the inclusion and exclusion criteria considering the endpoint PFS6. Details of the number of patients in the training and independent test set are providedBack to article page